1. Picardo M, Dell’Anna ML, Ezzedine K, Hamzavi I, Harris JE, Parsad D, Taieb A. Vitiligo. Nat Rev Dis Primers 2015;1:15011.
2. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet 2015;386:74-84.
3. Bae JM, Lee SC, Kim TH, Yeom SD, Shin JH, Lee WJ, Lee MH, Lee AY, Kim KH, Kim MB, Park CJ, Lee SH, Kim DH, Lee HJ, Lee DY, Choi CW, Kim YC, Kang HY, Haw S, Lee YB, Yun SJ, Yun SK, Hong SP, Lee Y, Kim HJ, Choi GS. Factors affecting quality of life in patients with vitiligo: a nationwide study. Br J Dermatol 2018;178:238-244.
4. Choi CW, Eun SH, Choi KH, Bae JM. Increased risk of comorbid rheumatic disorders in vitiligo patients: A nationwide population-based study. J Dermatol 2017;44:909-913.
5. Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE; Vitiligo Working Group. Current and emerging treatments for vitiligo. J Am Acad Dermatol 2017;77:17-29.
6. Bleuel R, Eberlein B. Therapeutic management of vitiligo. J Dtsch Dermatol Ges 2018;16:1309-1313.
7. Choi CW, Chang SE, Bak H, Choi JH, Park HS, Huh CH, Kim CW, Kim SE, Mun SK, Kim BJ, Kim MN. Topical immunomodulators are effective for treatment of vitiligo. J Dermatol 2008;35:503-507.
9. Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003;139:581-585.
10. Bae JM, Hong BY, Lee JH, Lee JH, Kim GM. The efficacy of 308-nm excimer laser/light (EL) and topical agent combination therapy versus EL monotherapy for vitiligo: a systematic review and meta-analysis of randomized controlled trials (RCTs). J Am Acad Dermatol 2016;74:907-915.
11. Mehrabi D, Pandya AG. A randomized, placebo-controlled, double-blind trial comparing narrowband UV-B plus 0.1% tacrolimus ointment with narrowband UV-B plus placebo in the treatment of generalized vitiligo. Arch Dermatol 2006;142:927-929.
12. Nicolaidou E, Antoniou C, Stratigos AJ, Stefanaki C, Katsambas AD. Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. J Am Acad Dermatol 2007;56:274-278.
13. Cavalie M, Ezzedine K, Fontas E, Montaudie H, Castela E, Bahadoran P, Taïeb A, Lacour JP, Passeron T. Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study. J Invest Dermatol 2015;135:970-974.
14. Kim SM, Lee HS, Hann SK. The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patients. Int J Dermatol 1999;38:546-550.
15. van der Veen W, van Geel N, Whitton M, Wolkerstorfer A, Picardo M; Vitiligo European Task Force (VETF); European Academy of Dermatology and Venereology (EADV); Union Europeenne des Medecins Specialistes (UEMS). Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol 2013;168:5-19.
16. Radakovic-Fijan S, Furnsinn-Friedl AM, Honigsmann H, Tanew A. Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol 2001;44:814-817.
17. Singh H, Kumaran MS, Bains A, Parsad D. A Randomized comparative study of oral corticosteroid minipulse and lowdose oral methotrexate in the treatment of unstable vitiligo. Dermatology 2015;231:286-290.
18. Taneja A, Kumari A, Vyas K, Khare AK, Gupta LK, Mittal AK. Cyclosporine in treatment of progressive vitiligo: an open-label, single-arm interventional study. Indian J Dermatol Venereol Leprol 2019;85:528-531.
19. Krutmann J, Morita A, Elmets CA. Mechanisms of photo (chemo)therapy. In: Krutmann J, Honigsmann H, Elmets CA, editor. Dermatological phototherapy and photodiagnostic methods. Berlin: Springer; 2009. p. 63-77.
20. Passeron T, Ostovari N, Zakaria W, Fontas E, Larrouy JC, Lacour JP, Ortonne JP. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 2004;140:1065-1069.
22. Gawkrodger DJ, Ormerod AD, Shaw L, Mauri-Sole I, Whitton ME, Watts MJ, Anstey AV, Ingham J, Young K; Therapy Guidelines and Audit Subcommittee; British Association of Dermatologists; Clinical Standards Department, Royal College of Physicians of London; Cochrane Skin Group; Vitiligo Society. Guideline for the diagnosis and management of vitiligo. Br J Dermatol 2008;159:1051-1076.
23. Bae JM, Ju HJ, Lee RW, Oh SH, Shin JH, Kang HY, Park JH, Kim HJ, Jeong KH, Lee HJ, Lee S, Kim DH, Lee DY, Kim YC, Choi GS, Kim KH, Park CJ, Choi CW; Korean Society of Vitiligo. Evaluation for skin cancer and precancer in patients with vitiligo treated with long-term narrowband UV-B phototherapy. JAMA Dermatol 2020;156:529-537.
24. Bae JM, Eun SH, Oh SH, Shin JH, Kang HY, Kim KH, Lee SC, Choi CW. The 308-nm excimer laser treatment does not increase the risk of skin cancer in patients with vitiligo: a population-based retrospective cohort study. Pigment Cell Melanoma Res 2019;32:714-718.
25. Mohammad TF, Al-Jamal M, Hamzavi IH, Harris JE, Leone G, Cabrera R, Lim HW, Pandya AG, Esmat SM. The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo. J Am Acad Dermatol 2017;76:879-888.
26. Oiso N, Suzuki T, Wataya-Kaneda M, Tanemura A, Tanioka M, Fujimoto T, Fukai K, Kawakami T, Tsukamoto K, Yamaguchi Y, Sano S, Mitsuhashi Y, Nishigori C, Morita A, Nakagawa H, Mizoguchi M, Katayama I. Guidelines for the diagnosis and treatment of vitiligo in Japan. J Dermatol 2013;40:344-354.
28. Linthorst Homan MW, Spuls PI, Nieuweboer-Krobotova L, de Korte J, Sprangers MA, Bos JD, Wolkerstorfer A, van der Veen JP. A randomized comparison of excimer laser versus narrowband ultraviolet B phototherapy after punch grafting in stable vitiligo patients. J Eur Acad Dermatol Venereol 2012;26:690-695.
29. Frisoli ML, Harris JE. Vitiligo: mechanistic insights lead to novel treatments. J Allergy Clin Immunol 2017;140:654-662.
30. Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA Dermatol 2015;151:1110-1112.